Sitagliptin counteracts seasonal fluctuation of glycemic control

Abstract

AIM:To assess the effect of sitagliptin therapy on seasonal fluctuation of glycemic control in Japanese type 2 diabetic patients. METHODS:Participating patients (age: 29-80 years) had been treated with conventional oral antidiabetic agents and/or diet and exercise therapy for over 6 mo. From December 2009, 35 patients were additionally prescribed oral sitagliptin starting from 50 mg once daily, while 19 patients taking α-glucosidase inhibitors were switched to sitagliptin. Twenty-four patients who refused sitagliptin formed the control group. Changes of mean monthly hemoglobin A1c (HbA1c) during the "winter holiday season" were compared between groups using Student's t -test (2008-2009 vs 2009-2010). Statistical significance was accepted at � < 0.05. �ulti�ariate 0.05. �ulti�ariate analysis was performed to assess whether sitagliptin use was associated with deterioration or improvement of glycemic control. RESULTS:Both add-on sitagliptin and switching from α-glucosidase inhibitors to sitagliptin prevented the seasonal deterioration of glycemic control and tended to improve HbA1c. Multivariate analysis revealed that both adding and switching to sitagliptin were negatively correlated with deterioration of glycemic control. In 44 patients who continued sitagliptin therapy for another year, elevation of HbA1c was suppressed without adverse effects. CONCLUSION:Sitagliptin is a suitable oral agent for preventing deterioration of glycemic control during the winter holiday season.

Analysis of the effect of seasonal administration on the efficacy of sitagliptin: Subanalysis of the Januvia Multicenter Prospective Trial in Type 2 Diabetes Study

“…Matsuhashi et al . administered sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to patients in December and compared the HbA1c level with that in February the next year; they paid particular attention to increases in HbA1c occurring during winter.…”

“…administered sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to patients in December and compared the HbA1c level with that in February the next year; they paid particular attention to increases in HbA1c occurring during winter. Consequently, HbA1c increased by 0.22% in a group in which previous treatment was continued, and increased 0.13% in a group in which the therapy was switched to sitagliptin during winter. Furthermore, HbA1c was decreased by 0.08% in a group in which sitagliptin was add‐on therapy.…”

“…Consequently, HbA1c increased by 0.22% in a group in which previous treatment was continued, and increased 0.13% in a group in which the therapy was switched to sitagliptin during winter. Furthermore, HbA1c was decreased by 0.08% in a group in which sitagliptin was add‐on therapy. Matsuhashi et al .…”

“…Furthermore, HbA1c was decreased by 0.08% in a group in which sitagliptin was add‐on therapy. Matsuhashi et al . demonstrated the ability of sitagliptin to decrease blood glucose levels in winter.…”